Aggressive variants of castration-resistant prostate cancer.

Journal Article (Journal Article;Review)

A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)-independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly rising serum prostate-specific antigen level. Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression and, in some cases, express markers of neuroendocrine differentiation. Because tumor morphology is not always predicted by clinical behavior, the terms "anaplastic prostate cancer" or "neuroendocrine prostate cancer" have been used descriptively to describe these rapidly growing clinical features. Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens. Therefore, understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications.

Full Text

Duke Authors

Cited Authors

  • Beltran, H; Tomlins, S; Aparicio, A; Arora, V; Rickman, D; Ayala, G; Huang, J; True, L; Gleave, ME; Soule, H; Logothetis, C; Rubin, MA

Published Date

  • June 1, 2014

Published In

Volume / Issue

  • 20 / 11

Start / End Page

  • 2846 - 2850

PubMed ID

  • 24727321

Pubmed Central ID

  • PMC4040316

Electronic International Standard Serial Number (EISSN)

  • 1557-3265

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-3309


  • eng

Conference Location

  • United States